The study is a Investigator Initiated Trial (IIT)/Other clinical trial of a class 2a medical device according to article 82 medical devices regulation of the European Union.~The aim of risk-adapted treatment (RAB) arm is to reduce the number of patients with an increased clinical risk for psychosis (ICD-10: schizophrenic disorders F2x.x, affective disorders F3x.3) to actually develop a manifest psychosis.~Patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing.~The AI-supported algorithm pronia.ai uses information from both the individual patient data of the specialized routine diagnostics as well as from in-depth clinical diagnostics.~There are two predictions, an individual quantitative assessment of the individual risk of transition to psychosis and the individual prognosis with regard to the level of psychosocial functioning 12 months after inclusion in the study.~The therapists and patients receive a non-binding risk profile from the AI-based recommendation to adjust the treatment intensity from 16 to 24 sessions over a period of six months.~The cognitive behavioral therapy-based manual Integrated Preventive Psychological Preventive Psychological Intervention (IPPI) manual is used. In the treatment-as-usual arm (TAU),the patients receive referral back to the previous care system; further treatment (and additional diagnostics, if necessary) is left to the referring primary care providers.
Multicenter randomized controlled trial (RCT) with artificial intelligence (AI)-staged early diagnostics and risk-adapted treatment (RAB) as interventional treatment arm and treatment-as-usual (TAU) as control treatment arm for patients with an increased clinical risk for psychosis.